BIIB vs. LLY: Biogen vs. Eli Lilly Stock Comparison
This page compares Biogen (BIIB) with Eli Lilly (LLY) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| 1-Year Return | 51.20% | 40.51% |
Risk
Drawdown
Risk at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| 1-Year Volatility | 33.53% | 38.09% |
| Beta | 0.17 | 0.51 |
| 3-Month Avg. Volume | 1.16M | 3.19M |
Company Profile
Biogen (BIIB) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while LLY is classified in Pharmaceuticals.
| Profile Item | BIIB | LLY |
|---|---|---|
| Name | Biogen Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 29.53 billion USD | 1,010.34 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | September 17, 1991 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Biogen (BIIB) at 21.51 and Eli Lilly (LLY) at 40.32 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.51
- Max
- 77.14
- Q3
- 43.78
- Median
- 24.68
- BIIB
- 21.51
- Q1
- 15.27
- Min
- 1.70
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.32
- Max
- 77.14
- Q3
- 43.78
- LLY
- 40.32
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
Price-to-Sales Ratio (TTM)
Biogen (BIIB) at 2.97 sits in the cheaper P/S ratio quartile while Eli Lilly (LLY) at 13.98 prices around its industry’s middle — BIIB costs less per dollar of sales, though read it alongside growth and margins.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- Q1
- 3.30
- BIIB
- 2.97
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.98
- Max
- 55.38
- Q3
- 24.42
- LLY
- 13.98
- Median
- 6.98
- Q1
- 3.30
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Biogen (BIIB) at 1.58 sits in the lower P/B ratio quartile relative to book while Eli Lilly (LLY) at 32.45 prices above its industry range — a wide valuation gap against assets.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- BIIB
- 1.58
- Min
- -5.17
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.45
- LLY
- 32.45
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
Valuation at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.51 | 40.32 |
| Price-to-Sales Ratio (TTM) | 2.97 | 13.98 |
| Price-to-Book Ratio (MRQ) | 1.58 | 32.45 |
| Free Cash Flow Yield | 6.54% | 0.91% |
Profitability
Return on Equity (TTM)
Both companies show strong equity returns, but Eli Lilly (LLY) at 107.46% is the standout with ROE above its industry range; Biogen (BIIB) at 7.70% also sits in the top quartile.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.70%
- Max
- 101.32%
- BIIB
- 7.70%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- LLY
- 107.46%
- Max
- 101.32%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Net Profit Margin (TTM)
Both Biogen (BIIB) at 13.81% and Eli Lilly (LLY) at 34.99% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.81%
- BIIB
- 13.81%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- LLY
- 34.99%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Operating Profit Margin (TTM)
Both Biogen (BIIB) at 22.90% and Eli Lilly (LLY) at 49.39% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.90%
- Max
- 100.30%
- BIIB
- 22.90%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- LLY
- 49.39%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Profitability at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| Return on Equity (TTM) | 7.70% | 107.46% |
| Return on Assets (TTM) | 5.95% | 20.74% |
| Net Profit Margin (TTM) | 13.81% | 34.99% |
| Operating Profit Margin (TTM) | 22.90% | 49.39% |
| Gross Profit Margin (TTM) | 78.72% | 82.83% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| 1-Year Revenue Growth | 2.22% | 44.70% |
| 3-Year Revenue CAGR | -0.94% | 31.69% |
EPS Growth
EPS Growth at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| 1-Year EPS Growth | -21.38% | 95.99% |
| 3-Year EPS CAGR | -25.04% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Biogen (BIIB) at 3.07 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.07
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- BIIB
- 3.07
- Q1
- 2.69
- Min
- 0.23
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- LLY
- 1.50
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Biogen (BIIB) at 0.35 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.39 uses more debt funding than most peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.60
- Q3
- 0.68
- BIIB
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- LLY
- 1.39
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| Current Ratio (MRQ) | 3.07 | 1.50 |
| Debt-to-Equity Ratio (MRQ) | 0.35 | 1.39 |
| Net Debt / EBITDA | 0.64 | 1.05 |
Dividends
Dividend Yield (TTM)
Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.61%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61%
- LLY
- 0.61%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 22.13%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- LLY
- 22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | BIIB | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.61% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.13% |